A white paper released last week by Eye on FDA/Fleishman-Hillard, "FDA Communications Oversight in a Digital Era," scrutinizes how the FDA/Office of Prescription Drug Promotion is enforcing advertising and promotion rules for digital and social media. In the absence of FDA guidance in this area, Mark Senak, Eye on FDA author and senior vice president and partner at Fleishman-Hillard, set out to determine how digital communications violations compared to violations by traditional (non-digital) communications vehicles for the period of 2008-2012. "There are still more questions than answers," said Coalition for Healthcare Communication Executive Director John Kamp, "but this paper sheds some important light onto the patterns of enforcement of digital over non-digital communications." Read more.